SELLAS revises REGAL trial SAP; observed OS ~2-fold longer, enrollment to 125-140

SELLAS Life Sciences Group, Inc.

Pooled blinded data shows overall survival ~2-fold longer than original protocol assumption; interim analysis reduced to 60 events, final to 80.
Enrollment target increased from 116 to 125-140 patients; partner 3D Medicines to add ~20 patients from China.
Milestone payments from 3DMed expected in H1 2023; potential for earlier China market entry if REGAL meets endpoints.
Q3 2022 net loss $7.0M ($0.34 per share); cash and equivalents $21.3M as of Sep 30, 2022.
Company hosting virtual investor event on REGAL update at 8:30 a.m. ET today.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SELLAS Life Sciences Group, Inc. reported quarter ended September 30, 2022 results: net income Net loss was $7.0 million for the third quarter of 2022, or a basic and diluted loss per share of $0.34.

Period: quarter ended September 30, 2022
Net income: Net loss was $7.0 million for the third quarter of 2022, or a basic and diluted loss per share of $0.34
Result: reported results

Exact text from the filing

On November 14, 2022, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2022 and providing a corporate update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001390478-22-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.